22:
103:) could benefit from the treatment. Subsequent investigation of the beneficial effects hydroxyurea in people with sickle cell disease has revealed multiple mechanisms (including suppression of inflammatory white blood cells and platelets), but increased levels of hemoglobin F are still thought to play a significant part.
80:, the main form of hemoglobin in adults. When cells sickle they can cause recurrent episodes of acute pain that often require hospitalization, transfusions, and strong pain medication. There is no cure. In the early 1980s a team led by Charache began testing a few patients at Hopkins to see if
115:. She became a noted physician, served on the Hopkins faculty for more than 50 years, and retired as a Distinguished Professor Emeritus of Pathology, Medicine, and Oncology. They were married for 64 years until her death in 2015, and had one child. He died January 29, 2019, at the age of 89.
76:. The disease gets its name from its effect on red blood cells, which become distorted from their normal round shape into pointed, sickle-shaped cells due to a mutation affecting
493:
72:
He is best known for his discovery of a treatment for sickle cell disease, a hereditary blood disorder that affects more than 70,000 people in the United States, primarily
95:
The results were encouraging, so in the 1990s he and a colleague, pediatrician George Dover, who had been researching sickle cell disease for 20 years, launched a
99:. The result was such a dramatic improvement in the condition of the test group that the trial was halted early, so that the control subjects (those receiving a
373:
Samuel
Charache; Michael L. Terrin; Richard D. Moore; George J. Dover; Franca B. Barton; Susan V. Eckert; Robert P. McMahon; Duane R. Bonds (May 18, 1995).
84:, a cancer drug, would help to abate the symptoms of the disease. They found that hydroxyurea treatment could increase recipients' blood levels of
25:
From left: Drs. Michael Terrin, Samuel
Charache, Duane Bonds and Claude Lenfant, NHLBI director, announce treatment for sickle cell disease in 1995
264:
Charache, S.; Dover, G. J.; Moore, R. D.; Eckert, S.; Ballas, S. K.; Koshy, M.; Milner, P. F.; Orringer, E. P.; Phillips, G. (May 15, 1992).
242:
498:
209:
478:
57:
180:
415:
483:
416:"Dr. Patricia 'Pat' Charache, 85, Hopkins infectious diseases specialist, medical microbiologist and educator, dies"
488:
473:
448:
136:
503:
316:
Agrawal, Rohit Kumar; Patel, Rakesh
Kantilal; Shah, Varsha; Nainiwal, Lalit; Trivedi, Bhadra (June 2014).
60:
in 1955. He joined the Johns
Hopkins faculty in 1966 and became director of the hematology department of
96:
210:"New Sickle Cell Treatment Helps Patients Ward Off Pain / Oakland, S.F. took part in clinical trial"
21:
37:
64:
in 1969. He was a professor in the departments of both pathology and medicine, retiring in 1995.
444:
372:
61:
44:, a painful and sometimes fatal blood disorder that mainly affects people of African ancestry.
92:(and normally only at low levels in adults) that is not affected by the sickle cell mutation.
468:
463:
234:
8:
41:
350:
317:
396:
355:
337:
295:
287:
266:"Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia"
112:
73:
386:
345:
329:
282:
277:
265:
53:
391:
375:"Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia"
374:
333:
457:
341:
291:
40:. He led the research team that discovered the first effective treatment for
359:
85:
77:
33:
400:
299:
81:
100:
89:
111:
While still an undergraduate at
Oberlin he met and married
315:
263:
494:
New York
University Grossman School of Medicine alumni
32:(January 12, 1930 – January 29, 2019) was an American
322:
Indian
Journal of Hematology & Blood Transfusion
163:There Are Many Colleges. There Is Only One Oberlin
318:"Hydroxyurea in sickle cell disease: drug review"
455:
154:
16:American hematologist and professor (1930–2019)
414:Rasmussen, Frederick N. (September 15, 2019).
311:
309:
88:, a form of hemoglobin primarily made by the
306:
413:
390:
349:
281:
239:National Heart, Lung, and Blood Institute
174:
172:
203:
201:
161:"Because of Oberlin". Oberlin Outcomes.
20:
207:
178:
165:. Oberlin, Ohio: Oberlin College. 2024.
52:He received his bachelor's degree from
456:
169:
67:
58:New York University School of Medicine
198:
137:"Hopkins finds sickle cell treatment"
130:
128:
179:Bennett, Kelsey (February 8, 2019).
134:
135:Sugg, Diana K. (January 31, 1995).
13:
245:from the original on March 6, 2016
125:
14:
515:
437:
56:in 1951 and his M.D. degree from
499:Johns Hopkins University faculty
106:
447:interview with Charache by the
379:New England Journal of Medicine
208:Perlman, David (May 19, 1995).
407:
366:
283:10.1182/blood.V79.10.2555.2555
257:
235:"What Is Sickle Cell Disease?"
227:
181:"Farewell to Dr. Sam Charache"
1:
479:Physicians from New York City
449:National Institutes of Health
118:
113:Patricia Connamacher Charache
7:
392:10.1056/nejm199505183322001
10:
520:
484:Physicians from Baltimore
334:10.1007/s12288-013-0261-4
97:controlled clinical trial
47:
38:Johns Hopkins University
214:San Francisco Chronicle
489:Oberlin College alumni
474:American hematologists
62:Johns Hopkins Hospital
26:
24:
504:Sickle-cell disease
185:Hopkinsmedicine.org
68:Sickle cell disease
42:sickle cell disease
27:
385:(20): 1318–1322.
276:(10): 2555–2565.
241:. June 12, 2015.
74:African Americans
36:and professor at
511:
431:
430:
428:
426:
411:
405:
404:
394:
370:
364:
363:
353:
313:
304:
303:
285:
261:
255:
254:
252:
250:
231:
225:
224:
222:
220:
205:
196:
195:
193:
191:
176:
167:
166:
158:
152:
151:
149:
147:
132:
519:
518:
514:
513:
512:
510:
509:
508:
454:
453:
440:
435:
434:
424:
422:
412:
408:
371:
367:
314:
307:
262:
258:
248:
246:
233:
232:
228:
218:
216:
206:
199:
189:
187:
177:
170:
160:
159:
155:
145:
143:
133:
126:
121:
109:
70:
54:Oberlin College
50:
30:Samuel Charache
17:
12:
11:
5:
517:
507:
506:
501:
496:
491:
486:
481:
476:
471:
466:
452:
451:
439:
438:External links
436:
433:
432:
406:
365:
305:
256:
226:
197:
168:
153:
123:
122:
120:
117:
108:
105:
69:
66:
49:
46:
15:
9:
6:
4:
3:
2:
516:
505:
502:
500:
497:
495:
492:
490:
487:
485:
482:
480:
477:
475:
472:
470:
467:
465:
462:
461:
459:
450:
446:
442:
441:
421:
420:Baltimore Sun
417:
410:
402:
398:
393:
388:
384:
380:
376:
369:
361:
357:
352:
347:
343:
339:
335:
331:
327:
323:
319:
312:
310:
301:
297:
293:
289:
284:
279:
275:
271:
267:
260:
244:
240:
236:
230:
215:
211:
204:
202:
186:
182:
175:
173:
164:
157:
142:
141:Baltimore Sun
138:
131:
129:
124:
116:
114:
107:Personal life
104:
102:
98:
93:
91:
87:
83:
79:
75:
65:
63:
59:
55:
45:
43:
39:
35:
31:
23:
19:
445:oral history
423:. Retrieved
419:
409:
382:
378:
368:
328:(2): 91–96.
325:
321:
273:
269:
259:
247:. Retrieved
238:
229:
217:. Retrieved
213:
188:. Retrieved
184:
162:
156:
144:. Retrieved
140:
110:
94:
86:hemoglobin F
78:hemoglobin A
71:
51:
34:hematologist
29:
28:
18:
469:2019 deaths
464:1930 births
82:hydroxyurea
458:Categories
219:August 25,
190:August 25,
146:August 26,
119:References
342:0971-4502
292:0006-4971
425:July 28,
360:24839362
249:March 8,
243:Archived
401:7715639
351:4022916
300:1375104
101:placebo
399:
358:
348:
340:
298:
290:
48:Career
270:Blood
90:fetus
427:2019
397:PMID
356:PMID
338:ISSN
296:PMID
288:ISSN
251:2016
221:2019
192:2019
148:2019
443:An
387:doi
383:332
346:PMC
330:doi
278:doi
460::
418:.
395:.
381:.
377:.
354:.
344:.
336:.
326:30
324:.
320:.
308:^
294:.
286:.
274:79
272:.
268:.
237:.
212:.
200:^
183:.
171:^
139:.
127:^
429:.
403:.
389::
362:.
332::
302:.
280::
253:.
223:.
194:.
150:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
